Royalty Pharma plc Other Liabilities
Royalty Pharma plc (RPRX) had Other Liabilities of $11.30 million as of 2023-09-30, per its 10-Q filed 2023-11-08.
Discontinued › Balance Sheet › Liabilities
us-gaap:OtherLiabilities · last filed 2023-11-08
- 2023-09-30: Other Liabilities $11.30M.
- 2023-06-30: Other Liabilities $8.50M.
- 2023-03-31: Other Liabilities $12.30M.
- 2022-12-31: Other Liabilities $2.50M.
| Period end | Other Liabilities |
|---|---|
| 2023-09-30 | $11.30M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $8.50M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $12.30M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $2.50M 10-Q · filed 2023-11-08 |
| 2022-09-30 | $9.90M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $43.70M 10-Q · filed 2022-08-04 |
| 2021-12-31 | $0.00 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |